Shannon Maude
Overview
Explore the profile of Shannon Maude including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghobadi A, Aldoss I, Maude S, Bhojwani D, Wayne A, Bajel A, et al.
Res Sq
. 2024 Aug;
PMID: 39149468
Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T cell product generated from healthy donor T...
2.
Pearson A, Rossig C, Mackall C, Shah N, Baruchel A, Reaman G, et al.
Eur J Cancer
. 2021 Nov;
160:112-133.
PMID: 34840026
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially...
3.
Gofshteyn J, Shaw P, Teachey D, Grupp S, Maude S, Banwell B, et al.
Ann Neurol
. 2018 Sep;
84(4):537-546.
PMID: 30178481
Objective: To characterize the incidence and clinical characteristics of neurotoxicity in the month following CTL019 infusion in children and young adults, to define the relationship between neurotoxicity and cytokine release...
4.
Burstein D, Maude S, Grupp S, Griffis H, Rossano J, Lin K
Biol Blood Marrow Transplant
. 2018 May;
24(8):1590-1595.
PMID: 29772353
Immunotherapy with chimeric antigen receptor (CAR)-modified T cells targeting CD19 for pediatric acute lymphoblastic leukemia (ALL) has demonstrated significant efficacy. The principle toxicity is cytokine release syndrome with resultant hypotension....
5.
Maude S, Barrett D
Br J Haematol
. 2015 Nov;
172(1):11-22.
PMID: 26560054
The field of adoptive cell transfer includes chimeric antigen receptor (CAR) engineered T cells, constructs that emerged from basic research into principles of immunology and have transformed into clinically effective...
6.
Qin H, Cho M, Haso W, Zhang L, Tasian S, Oo H, et al.
Blood
. 2015 Jun;
126(5):629-39.
PMID: 26041741
Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting the CD19 B cell-associated protein have demonstrated potent activity against relapsed/refractory B-lineage acute lymphoblastic leukemia (B-ALL)....